Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Experts on Generic Pharmaceuticals: Pharmacists

Articles with lock require a subscription to GLG News | Request a free trial
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Author: David Zimmerman, President/Owner, Doctors of Pharmacy, Inc.
This drug will allow patients in severe pain to get the necessary pain relief and not have to worry about the other patients that abuse the drug.
May 15, 2008
Reverse Payments for PHRMA smell fishy
Analysis of: US trade agency wants to end deals delaying generics | www.reuters.com
Author: Bruce Goldberg, President, Pharmacy Express Services, Inc.
Our FTC has gone on record once again stating that the so called "Phrma reverse payments" to generic manufacturers breach antitrust regulations. Delaying competition by simply paying off another supplier, leads to higher prices for me, you, and our families.  My grandpa used to call this stuff...
April 14, 2008
Cubicin not tainted but delivery device.
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: GLG Expert Contributor
            ReadyMED® is a infusion device used primarily in outpatient settings for administering antiobiotics in the home.  ReadyMED® requires little patient or caregiver training and works by gravity.  No IV poles or pumps...
March 10, 2008
POTENTIAL PARADYM SHIFT IN MANAGEMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
Analysis of: Abbott Receives FDA Approval for Humira (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis | pharmalive.com
Author: GLG Expert Contributor
Historically JIA (commonly called Juvenile Rheumatoid Arthritis or JRA) has confounded the medical community for decades. All DMARDS (Disease Modifying Anti Rheumatic Drugs) have been noted for their toxicity and no clinician or parent really wants to consider their use in a pediatric population for...
February 11, 2008
Fosamax generic...
Analysis of: Teva wins FDA OK to sell generic Fosamax | www.reuters.com
Author: David Zimmerman, President/Owner, Doctors of Pharmacy, Inc.
It is important to understand the generic implications when it comes to drug product olacement on the formulary.
February 11, 2008
Zyprexa safety
Analysis of: FDA Advisory Committee Supports Efficacy and Safety of Zyprexa | www.fiercebiotech.com
Author: David Zimmerman, President/Owner, Doctors of Pharmacy, Inc.
This article is informative because it draws conclusions about Zyprexa.
Dea BelaziJanuary 28, 2008
Erythropoiesis Stimulating Agents could be further restricted by Payers (Medicare, PBMs, and Healthplans)
Analysis of: FDA Receives New Data on Risks of Anemia Drugs | www.fda.gov
Author: Dea Belazi, Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM
Increased FDA warnings on ESAs, suchas Epogen, Procrit and Aranesp will provide payers the ability to further restrict these agents.   Restrictions will come in the form of prior authorizations and other utilization management techniques.
January 11, 2008
daily use Cialis---a good idea!
Analysis of: Cialis Is Cleared for Daily Use | online.wsj.com
Author: David Zimmerman, President/Owner, Doctors of Pharmacy, Inc.
    Physicians have been prescribing lower dose Cialis...off label... for a long time. The FDA finally agreed and approved it.
Tim GallagherNovember 1, 2007
Should We Treat Colds In Children?
Analysis of: Cough-Medicine Dilemma Widens | online.wsj.com
Author: Tim Gallagher, Executive Vice President of Pharmacy Operations , Astrup Drug, Inc.
An FDA advisory panel recently voted to stop the recommendation of otc cough and cold products in children less than 12 years of age. For decades parents have administered otc cough and could products to infants and young children. Even the FDA Advisory Committee had dissention amongst their members,...
Dea BelaziOctober 29, 2007
Perhaps the Most Important Reason for Exubera Failure is that No One Wanted to Pay for it
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: Dea Belazi, Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM
Pfizers failure on Exubera were not of safety issues, or complicated device, or even consumer marketing problems.  Their biggest issue that brought failure was the lack of payer coverage.  Almost no payer in the US added Exubera to their formulary or saw any value over injectable insulin...

Page : 1 2 3 4 Next1 to 10 of 33

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163